Profile
Mark J.
Bachleda worked as a Vice President at Bristol Myers Squibb Co. and as a Vice President-Sales & Account Management at Juno Therapeutics, Inc. He also worked as a Chief Commercial Officer at Galera Therapeutics, Inc. from 2021 to 2023.
Bachleda holds an MBA from the University of California, Berkeley and a doctorate from the University of Illinois.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 20/04/2023 | 11,000 ( 0.02% ) | 2 277 $ | 29/04/2024 |
Former positions of Mark Bachleda
| Companies | Position | End |
|---|---|---|
| GALERA THERAPEUTICS, INC. | Corporate Officer/Principal | 08/08/2023 |
| JUNO THERAPEUTICS INC | Sales & Marketing | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Training of Mark Bachleda
| University of Illinois | Doctorate Degree |
| University of California, Berkeley | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GALERA THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Mark Bachleda
